Regulatory Teva Receives FDA Approval of Denosumab Biosimilar and Filing Acceptances by FDA and EMA For Omalizumab Biosimilar Big Molecule WatchOn March 30, 2026, Teva Pharmaceutical Industries Ltd.RegulatoryRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) Big Molecule Watch On March 30, 2026, Teva Pharmaceutical Industries Ltd. RegulatoryRead full story Post navigation Previous: Lilly launches GLP-1 pill, kicking off showdown with Novo NordiskNext: Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026